Paul Boffetti, MD
Interventional Cardiology · Nashua, NHNPI 1548208846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $827 and has fallen 75.2% since, to $205 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NH, where the typical reported total is $5,309.
Across 106 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$511
- AstraZeneca$311
- Pfizer$225
- Novartis$196
- Abbott$168
- Penumbra, Inc.$163
- plus $939 from 19 others
Across 14 payments — averaging $1287.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$11K
- Esperion Therapeutics, Inc.$7K
What the payments were for
- Food & beverage$2,47598%
- Education$382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 29 | $511 |
| AstraZeneca | 15 | $311 |
| Pfizer | 10 | $225 |
| Novartis | 9 | $196 |
| Abbott | 3 | $168 |
| Penumbra, Inc. | 1 | $163 |
| Abiomed | 4 | $151 |
| E.r. Squibb & Sons, L.L.C. | 8 | $126 |
| Boston Scientific | 3 | $91 |
| Lantheus Medical Imaging, Inc. | 3 | $85 |
| Amgen | 4 | $80 |
| GE HealthCare | 2 | $68 |
| Baxter Healthcare | 1 | $55 |
| Boehringer Ingelheim | 2 | $48 |
| Siemens Medical Solutions USA, Inc. | 2 | $37 |
| Shockwave Medical, Inc | 1 | $30 |
| Recor Medical Inc | 1 | $25 |
| Chiesi USA, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| Teleflex LLC | 1 | $19 |
| Cardiva Medical, Inc. | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,512 in reported general payments places this provider in the 30th percentile of 26 interventional cardiology providers in New Hampshire.
See all interventional cardiology providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $114,691 |
| XareltoRivaroxaban | 53 | $70,004 |
| JardianceEmpagliflozin | 27 | $27,024 |
| EntrestoSacubitril/Valsartan | 22 | $26,005 |
| FarxigaDapagliflozin Propanediol | 27 | $25,292 |
| Repatha SureclickEvolocumab | 11 | $5,873 |
| Ezetimibe | 57 | $2,207 |
| Metoprolol Succinate | 155 | $2,004 |
| Rosuvastatin Calcium | 66 | $1,350 |
| Torsemide | 33 | $754 |
| Atorvastatin Calcium | 74 | $739 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $696 |
| Flecainide Acetate | 14 | $685 |
| Carvedilol | 46 | $533 |
| Valsartan | 20 | $470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $225 | $114,691127 claims |
| Johnson & JohnsonXarelto | $511 | $70,00453 claims |
| Boehringer IngelheimJardiance | $48 | $27,02427 claims |
| NovartisEntresto | $196 | $26,00522 claims |
| AstraZenecaFarxiga | $311 | $25,29227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 26 interventional cardiology providers in New Hampshire.
Other interventional cardiology in Nashua
- Shahab MoossaviConcord$36K
- Nitish SharmaDover$23K
- Rodrigo Mendirichaga MaganaDover$21K
- Hannah ChaudryLebanon$20K
- Eric RothsteinLebanon$20K
- James DevriesLebanon$19K
- Xiaoyu Yang-GiulianoManchester$18K
- Lazaro DiazExeter$15K
- Aaron KaplanLebanon$13K
- Augustin DelagoConcord$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.